UBS raises Jazz Pharmaceuticals stock target to $307
UBS upgraded Jazz Pharmaceuticals two notches, from neutral to buy, and lifted its price target to $307 from $188.
This represents a 63% jump in one move, and it sits well above the prior analyst consensus of roughly $242.
The firm projects around $3.1 billion in peak Ziihera sales, helped by strong Phase 3 HERIZON-GEA data and a projected 45% peak penetration in its target market.
The $307 figure rests on two levers working together: higher growth and a higher multiple, with UBS now forecasting 10% revenue growth.